Anna Phillips-Waller

Anna Phillips-Waller

Auto-generated profile, based on publicly available information

Anna Phillips-Waller

Wolfson Institute of Population Health Queen Mary University of London London UK

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
29 January 2020 in Addiction
Verified
Journal Article
Open access
PDF file
PHPeter Hajek
Peter Hajek
KPKate Pittaccio
Kate Pittaccio
FPFrancesca Pesola
Francesca Pesola
KSKatie Myers Smith
Katie Myers Smith
APAnna Phillips‐Waller
Anna Phillips‐Waller
DPDunja Przulj
Dunja Przulj
Aims: To assess the pharmacokinetic (PK) profile of, and users’ reactions to, Juul (59 mg nicotine/ml) as an indication of its therapeutic and dependence potential.Design: Cross‐over, within‐subjects study in which participants attended after overnight abstinence on separate sessions and smoked a cigarette or used Juul or eight other types of e‐cigarettes (EC)ad libitumfor 5 minutes. The Juul product used was the version available in the United States that has more nicotine in the e‐liquid than the one available in the European Union.Setting: Laboratory setting in the United Kingdom.Participants: Twenty dual users (smokers who also vape) provided data on Juul and cigarettes, with eight also providing data on other EC products.Measurements: At each session, number of puffs taken was counted during the 5‐minute product use period and blood samples were taken at baseline and at 2, 4, 6, 8, 10 and 30 minutes after starting smoking/vaping and analysed for nicotine. Participants also monitored their urges to smoke and rated the products on a range of characteristics.Findings: Juul's PK profile was close to the PK profile of cigarettes [maximum concentration (Cmax) = 20.4 versus 19.2 ng/ml; time to maximum concentration (Tmax) = 4 versus 6 minutes; area under the curve (AUC): 307.9 versus 312.6, respectively]. Compared with other EC products, Juul had shorter Tmax[4 minutes, (IQR = 2.5–4.0) versus 6.3 minutes, (IQR = 4.7 – 8.1),P= 0.012] and higher Cmax(28.9 (SD = 15.6) versus 10.6 (SD = 5.5),P= 0.013) despite a lower number of puffs (12.5 (SD = 4.2) versus 17.0 (SD = 4.2),P= 0.084). Compared with other e‐cigarette products, it also provided faster reduction of urges to smoke and obtained more favourable subjective ratings.Conclusion: Juul's PK profile and user ratings suggest that it could be more effective than other EC products in helping smokers to quit smoking, but it may also have a higher potential to generate regular use in non‐smokers.

29 June 2021 in Addiction
Verified
Journal Article
Open access
PDF file
KSKatie Myers Smith
Katie Myers Smith
APAnna Phillips‐Waller
Anna Phillips‐Waller
FPFrancesca Pesola
Francesca Pesola
HMHayden McRobbie
Hayden McRobbie
DPDunja Przulj
Dunja Przulj
PHPeter Hajek
Peter Hajek
Background and aims: The majority of smokers accessing the current best treatments continue to smoke. We aimed to test if e‐cigarettes (EC) compared with nicotine replacement treatment (NRT) can help such smokers to reduce smoking.Design: Randomized controlled trial of EC (n = 68) versus NRT (n = 67) with 6‐month follow‐up.Setting: Stop smoking service in London, UK.Participants: A total of 135 smokers (median age = 40 years, 51% male) previously unable to stop smoking with conventional treatments.Interventions: Participants received either NRT of their choice (8‐week supply) or an EC starter pack and instructions to purchase further e‐liquids of strength and flavours of their choice themselves. Products were accompanied by minimal behavioural support.Measurements: Participants who reported that they stopped smoking or reduced their daily cigarette consumption by at least 50% at 6‐month follow‐up were invited to provide a carbon monoxide (CO) reading. The primary outcome was biochemically validated reduction in smoke intake of at least 50% at 6 months and the main secondary outcome was sustained validated abstinence at 6 months. Drop‐outs were included as ‘non‐reducers’.Findings: Validated smoking reduction (including cessation) was achieved by 26.5 versus 6.0% of participants in the EC and NRT study arms, respectively [relative risk (RR) = 4.4, P = 0.005, 95% confidence interval (CI) = 1.6–12.4]. Sustained validated abstinence rates at 6 months were 19.1 versus 3.0% (RR = 6.4, P = 0.01, 95% CI = 1.5–27.3). Product use was high and equal in both study arms initially, but at 6 months allocated product use was 47% in the EC arm versus 10% in the NRT arm (χ2(1) = 22.0, P < 0.001), respectively. Adverse events were minor and infrequent.Conclusions: In smokers unable to quit using conventional methods, e‐cigarettes were more effective than nicotine replacement therapy in facilitating validated long‐term smoking reduction and smoking cessation when limited other support was provided.

1 August 2019 in Health Technology Assessment
Verified
Journal Article
Closed access
PHPeter Hajek
Peter Hajek
APAnna Phillips-Waller
Anna Phillips-Waller
DPDunja Przulj
Dunja Przulj
FPFrancesca Pesola
Francesca Pesola
KSKatie Myers Smith
Katie Myers Smith
HMHayden J McRobbie
Hayden J McRobbie
Background: Over the past few years, a large number of smokers in the UK have stopped smoking with the help of e-cigarettes. So far, UK Stop Smoking Services (SSSs) have been reluctant to include e-cigarettes among their treatment options because data on their efficacy compared with the licensed medications are lacking.Objective: The objective was to compare the efficacy of refillable e-cigarettes and nicotine replacement therapy (NRT) products, when accompanied by weekly behavioural support.Design: A randomised controlled trial comparing e-cigarettes and NRT.Setting: Three sites that provide local SSSs.Participants: The participants were 886 smokers seeking help to quit smoking, aged ≥ 18 years, not pregnant or breastfeeding, with no strong preference to use or not to use NRT or e-cigarettes in their quit attempt, and currently not using NRT or e-cigarettes. A total of 886 participants were randomised but two died during the study (one in each study arm) and were not included in the analysis.Interventions: The NRT arm (n = 446) received NRT of their choice (single or combination), provided for up to 12 weeks. The e-cigarette arm (n = 438) received an e-cigarette starter pack and were encouraged to buy addtional e-liquids and e-cigarette products of their choice. Both arms received the same standard behavioural support. Participants attended weekly sessions at their SSS and provided outcome data at 4 weeks. They were then followed up by telephone at 6 and 12 months. Participants reporting abstinence or at least 50% reduction in cigarette consumption at 12 months were invited to attend for carbon monoxide (CO) validation. Participants/researchers could not be blinded to the intervention.Main outcome measures: The primary outcome was CO-validated sustained abstinence rates at 52 weeks. Participants lost to follow-up or not providing biochemical validation were included as non-abstainers. Secondary outcomes included abstinence at other time points, reduction in smoke intake, treatment adherence and ratings, elicited adverse reactions, and changes in self-reported respiratory health. A cost-efficacy analysis of the intervention was also conducted.Results: The 1-year quit rate was 9.9% in the NRT arm and 18.0% in the e-cigarette arm (risk ratio 1.83, 95% confidence interval 1.30 to 2.58;p < 0.001). The e-cigarette arm had significantly higher validated quit rates at all time points. Participants in the e-cigarette arm showed significantly better adherence and experienced fewer urges to smoke throughout the initial 4 weeks of their quit attempt than those in the NRT arm, and gave their allocated product more favourable ratings. They were also more likely to be still using their allocated product at 1 year (39.5% vs. 4.3%, χ2 = 161.4;p < 0.001). Participants assigned to e-cigarettes reported significantly less coughing and phlegm at 1 year than those assigned to NRT (controlling for smoking status). A detailed economic analysis confirmed that, because e-cigarettes incur lower NHS costs than NRT and generate a higher quit rate, e-cigarette use is more cost-effective.Limitations: The results may not be generalisable to other types of smokers or settings, or to cartridge-based e-cigarettes.Conclusions: Within the context of multisession treatment for smokers seeking help, e-cigarettes were significantly more effective than NRT. If SSSs provide e-cigarette starter packs, it is likely to boost their success rates and improve their cost-efficacy.Future work: The efficacy of e-cigarettes provided with different levels of support will show whether smokers should be encouraged to switch to vaping within support services or whether e-cigarettes can be recommended with less intensive or no support.Trial registration: Current Controlled Trials ISRCTN60477608.Funding: This project was funded by the National Institute for Health Research (NIHR) Health Technology Assessment programme and will be published in full inHealth Technology Assessment; Vol. 23, No. 43. See the NIHR Journals Library website for further project information. The trial was supported by the Cancer Research UK Prevention Trials Unit (grant A16893).

9 October 2019 in Addiction
Verified
Journal Article
Open access
PDF file
JLJinshuo Li
Jinshuo Li
PHPeter Hajek
Peter Hajek
FPFrancesca Pesola
Francesca Pesola
QWQi Wu
Qi Wu
APAnna Phillips‐Waller
Anna Phillips‐Waller
SPSteve Parrott
Steve Parrott
Aim: To evaluate the cost‐effectiveness of e‐cigarettes as a smoking cessation aid used in routine stop smoking services in England.Design: Cost‐effectiveness analysis was performed from the National Health Service (NHS) and Personal Social Services (PSS) perspective for 12‐month periods and life‐time. Costs, including that of both treatments, other smoking cessation help and health‐care services, and health benefits, estimated from EQ‐5D‐5L and measured in quality‐adjusted life‐years (QALYs), for the 12‐month analysis, came from a randomized controlled trial. Life‐time analysis was model‐based with input from both trial data and published secondary data sources. Cost‐effectiveness was measured by an incremental cost‐effectiveness ratio (ICER).Setting: Three stop‐smoking service sites in England.Participants: Adult smokers (n = 886) who sought help to quit in the participating sites.Intervention and comparator: An e‐cigarette (EC) starter kit versus provision of nicotine replacement therapy (NRT) for up to 3 months, both with standard behavioural support. A total of 886 participants were randomized (439 in the EC arm, 447 in the NRT arm). Excluding one death in each arm, the 1‐year quit rate was 18.0 and 9.9%, respectively.Measurements: Cost of treatments was estimated from the treatment log. Costs of other smoking cessation help and health‐care services and EQ‐5D‐5 L were collected at baseline, 6‐ and 12‐month follow‐ups. Incremental costs and incremental QALYs were estimated using regression adjusting for baseline covariates and their respective baseline values.Findings: The ICER was £1100 per QALY gained at the 12 months after quit date (87% probability below £20 000/QALY). Markov model estimated the life‐time ICER of EC to be £65 per QALY (85% probability below £20 000/QALY).Conclusion: Using e‐cigarettes as a smoking cessation aid with standard behavioural support in stop‐smoking services in England is likely to be more cost‐effective than using nicotine replacement therapy in the same setting.

3 December 2020 in Psychopharmacology
Verified
Journal Article
Open access
PDF file
APAnna Phillips-Waller
Anna Phillips-Waller
DPDunja Przulj
Dunja Przulj
KSKatie Myers Smith
Katie Myers Smith
FPFrancesca Pesola
Francesca Pesola
PHPeter Hajek
Peter Hajek
Rationale: The degree to which the EU version of Juul with 20 mg/ml nicotine (Juul EU) delivers nicotine to users is likely to determine its treatment potential. Objectives: To compare the pharmacokinetic profile and user ratings of Juul EU, Juul US (59 mg/ml nicotine), cigarettes and other e-cigarette (EC) products. Methods: In a within-subjects crossover design, 18 vapers used, at separate sessions, their own brand cigarette (OBC), Juul US and Juul EU for 5 min ad libitum, after overnight abstinence. Seven of the participants also tested eight other EC previously. Blood samples were taken at baseline and 2, 4, 6, 8, 10 and 30 min after initiating product use. Products were rated on a range of characteristics. Results: Juul EU delivered less nicotine than OBC (t(13) = −4.64 p < .001) and than Juul US (t(13) = −6.40, p < .001): AUC0 ≥ 30 77.3, 324.8 and 355.9, respectively. Maximum nicotine concentration (Cmax) was also much lower for Juul EU than Juul US (z = −3.59, p < .001): Cmax 3.8 ng/ml vs 21.1 ng/ml, respectively. Juul EU was perceived to relieve urges to smoke less than Juul US (z = −2.29, p = .022) and to provide less nicotine (z = −2.57. p = 0.010). Juul EU delivered less nicotine than refillable EC (Cmax: t(6) = 3.02, p = 0.023; AUC0 ≥ 30: z = −2.20, p = 0.028) and also less than cig-a-like EC, though the difference did not reach significance (Cmax: t(6) = 2.49, p = 0.047; AUC0 ≥ 30: z = −1.99, p = 0.046). Subjective ratings of Juul EU and other EC products were similar. Conclusions: Juul EU delivers much less nicotine to users than Juul US, and also less than refillable EC products. It may thus have more limited potential to help smokers quit.

13 May 2021 in Nicotine & Tobacco Research
Verified
Journal Article
Open access
PDF file
APAnna Phillips-Waller
Anna Phillips-Waller
DPDunja Przulj
Dunja Przulj
FPFrancesca Pesola
Francesca Pesola
KSKatie Myers Smith
Katie Myers Smith
PHPeter Hajek
Peter Hajek
Reduced-risk nicotine products are more likely to replace smoking if they match cigarettes in nicotine delivery and user satisfaction. We examined the nicotine delivery profile and user ratings of IQOS heated tobacco system and compared it with own brand cigarettes (OBC), Juul, and refillable e-cigarettes (EC).Participants (N = 22) who were daily vapers smoking <1 cigarette per day on average, attended after overnight abstinence from smoking and vaping, to test at separate sessions OBC, IQOS, and Juul. Eight participants also tested two refillable EC using e-liquid with 20 mg/mL nicotine. At each session, a baseline blood sample was taken before participants used the product ad libitum for 5 minutes. Further samples were taken at 2, 4, 6, 8, 10, and 30 minutes. Maximum nicotine concentration (Cmax), time to Cmax (Tmax), and nicotine delivered over 30 minutes (AUC0–>30) were calculated. Participants rated their urge to smoke and product characteristics. IQOS delivered less nicotine than OBC (AUC0–>30: z = −2.73, p = .006), and than Juul (AUC0–>30: z = −3.08, p = .002; Cmax: z = −2.65, p = .008), and received less favorable ratings than Juul (effect on urges to smoke: z = −3.23, p = .001; speed of urge relief: z = −2.75, p = .006; recommendation to friends: z = −2.45, p = .014). Compared with refillable EC, IQOS delivered nicotine faster (Tmax: z = −2.37, p = .018), but received less favorable overall ratings (recommended to friends: z = −2.32, p = .021). IQOS’ pharmacokinetic profile suggests that it may be less effective than Juul for smoking cessation, but at least as effective as refillable EC; although participants, who were experienced vapers rather than IQOS users, preferred refillable EC. Because IQOS provided less efficient nicotine delivery than cigarettes and Juul in this sample, and also had a weaker effect on urges to smoke than Juul, it could be less helpful than Juul in assisting such dual users, and possibly smokers generally, to switch to an alternative product. IQOS, however, provided nicotine faster than refillable EC products, although participants preferred EC.